Rapport Therapeutics, Inc. (RAPP) Prices $200M Equity, $150M 2.25% Convertible Notes
Rapport Therapeutics (RAPP) raised $175M via common stock at $21.00, $25M via pre-funded warrants, and $150M via 2.25% convertible notes due 2032, plus a $30M private placement. The funds will support RAP-219 trials and pipeline development, with key data expected from FOCUS 1/2 and bipolar mania trials.
How this was made
The 30-second read
Why it matters
The $200M raise introduces new equity and convertible debt, likely diluting existing shareholders and adding leverage.
Market read
Primary disclosure of a large capital raise; traders can act on dilution risk.
What to watch
Potential strategic investors or partnership terms not disclosed may mitigate dilution impact.
Background
Rapport Therapeutics is a clinical‑stage biotech seeking funds for RAP‑219 trials and pipeline development.
Ticker impact
Rapport Therapeutics announced a $200M equity and convertible note offering, a fresh primary capital raise.
likely downward pressure as market prices in dilution and increased leverage
The sizable, first‑report capital raise introduces new supply and debt, which typically depresses share price in the short term.
Market effects
May signal fundraising pressure for other clinical‑stage biotech firms.
Limited to US biotech investors.
Low, confined to niche biotech capital markets.
Counterpoint
The raise could fund pivotal trials that unlock significant upside if data are positive.
Key entities
- companyRapport Therapeutics, Inc.
Clinical‑stage biotech issuing equity and convertible notes.
